Exon-skipping antisense oligonucleotides for cystic fibrosis therapy

Author:

Kim Young Jin123ORCID,Sivetz Nicole1ORCID,Layne Jessica1ORCID,Voss Dillon M.123ORCID,Yang Lucia123ORCID,Zhang Qian14ORCID,Krainer Adrian R.1ORCID

Affiliation:

1. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724

2. Graduate Program in Genetics, Stony Brook University, Stony Brook, NY 11794

3. Medical Scientist Training Program, Stony Brook University School of Medicine, Stony Brook, NY 11794

4. Graduate Program in Molecular and Cell Biology, Stony Brook University, Stony Brook, NY 11794

Abstract

Significance Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, which can lead to respiratory failure. To date, there is no treatment for CF caused by the CFTR- W1282X mutation located on CFTR exon 23. Nonsense-mediated messenger RNA (mRNA) decay (NMD) degrades the CFTR- W1282X mRNA, leading to low levels of functional CFTR protein. We developed a cocktail of two antisense oligonucleotides (ASOs) that promotes the skipping of exon 23 of the CFTR- W1282X mRNA. The resulting mRNA is NMD resistant and preserves the reading frame. Its translation produces CFTR-Δex23 protein that improves CFTR activity in human bronchial epithelial cells. Our results set the stage for developing an ASO therapy for CF caused by the W1282X mutation.

Funder

HHS | NIH | National Institute of General Medical Sciences

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3